In vitro glucuronidation of Armillarisin A: UDP-glucuronosyltransferase 1A9 acts as a major contributor and significant species differences

References

• Albert C, Vallée M, Beaudry G, et al. (1999). The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology 140:3292–302
   PubMed Web of Science ®Google Scholar
• Buckley DB, Klaassen CD. (2007). Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab Dispos 35:121–7
   PubMed Web of Science ®Google Scholar
• Court MH. (2010). Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209–24
   PubMed Web of Science ®Google Scholar
• Court MH, Zhang X, Ding X, et al. (2012). Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 42:266–77
   PubMed Web of Science ®Google Scholar
• Fang ZZ, He RR, Cao YF, et al. (2013). A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders. J Lipid Res 54:3334–44
   PubMed Web of Science ®Google Scholar
• Furukawa T, Naritomi Y, Tetsuka K, et al. (2014). Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys. Xenobiotica 44:205–16
   PubMed Web of Science ®Google Scholar
• Guillemette C, Lévesque E, Harvey M, et al. (2010). UGT genomic diversity: beyond gene duplication. Drug Metab Rev 42:24–44
   PubMed Web of Science ®Google Scholar
• Harbourt DE, Fallon JK, Ito S, et al. (2012). Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal Chem 84:98–105
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ensom MH, Chang TK. (2005). UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol Ther 106:97–132
   PubMed Web of Science ®Google Scholar
• Li L, Hu H, Xu S, et al. (2012). Roles of UDP-glucuronosyltransferases in phytochemical metabolism of herbal medicines and the associated herb–drug interactions. Curr Drug Metab 13:615–23
   PubMed Web of Science ®Google Scholar
• Li W, Liu Y, He YQ, et al. (2008). Characterization of triptolide hydroxylation by cytochrome P450 in human and rat liver microsomes. Xenobiotica 38:1551–65
   PubMed Web of Science ®Google Scholar
• Li L, Wang SJ, Liu XH, et al. (2009). Determination of Armillarisin A in rat plasma by SPE and LC-MS-MS. Chrmatographia 70:1233–7
   Google Scholar
• Liang SC, Ge GB, Liu HX, et al. (2010). Identification and characterization of human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of daphnetin. Drug Metab Dispos 38:973–80
   PubMed Web of Science ®Google Scholar
• Ma XC, Ning J, Ge GB, et al. (2011). Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human. Drug Metab Dispos 39:675–82
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Bock KW, Burchell B, et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genom 15:677–85
   PubMed Web of Science ®Google Scholar
• Mi BL, Sun Q, Qu YQ, et al. (2014). Glucuronidation of aurantio-obtusin: identification of human UDP-glucuronosyltransferases and species differences. Xenobiotica. [Epub ahead of print]. doi: 10.3109/00498254.2014.895881
   Google Scholar
• Ohno S, Nakajin S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40
   PubMed Web of Science ®Google Scholar
• Rowland A, Miners JO, Mackenzie PI. (2013). The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45:1121–32
   PubMed Web of Science ®Google Scholar
• Shao HS, Zhang SR, Pan SR, et al. (1980). Absorption, distribution, excretion and metabolites of [14C]armillarisin A in rats. Zhongguo Yao Li Xue Bao 1:120–4
   PubMedGoogle Scholar
• Shelby MK, Cherrington NJ, Vansell NR, Klaassen CD. (2003). Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31:326–33
   PubMed Web of Science ®Google Scholar
• Soars MG, Riley RJ, Findlay KA, et al. (2001). Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos 29:121–6
   PubMed Web of Science ®Google Scholar
• Sun F, Su JD, Zheng H. (1981). Studies on the pharmacological activities and toxicities of armillarisin A, a new choleretic drug. Yao Xue Xue Bao 16:401–6
   PubMedGoogle Scholar
• Tracy TS. (2006). Atypical cytochrome p450 kinetics: implications for drug discovery. Drugs R D 7:349–63
   PubMedGoogle Scholar
• Uchaipichat V, Mackenzie PI, Guo XH, et al. (2004). Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413–23
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Li P, et al. (2007). Quantitation of Armillarisin A in human plasma by liquid chromatography-electrospray tandem mass spectrometry. J Pharm Biomed Anal 43:1860–3
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang ZH, Liu MY, et al. (2008). Absolute bioavailability of Armillarisin A in rats. J Jilin Univ (Section Edition) 46:154–6
   Google Scholar
• Xia YL, Liang SC, Zhu LL, et al. (2014). Identification and characterization of human UDP-Glucuronosyltransferases responsible for the glucuronidation of fraxetin. Drug Metab Pharmacokinet 29:135–40
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Mukai M, Nagaoka K, et al. (2014). Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9. Eur J Drug Metab Pharmacokinet. [Epub ahead of print]. doi: 10.1007/s13318-014-0177-x
   Google Scholar
• Zhang JW, Liu Y, Zhao JY, et al. (2008). Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos 36:2292–8
   PubMed Web of Science ®Google Scholar
• Zhang YY, Liu Y, Zhang JW, et al. (2009). Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39:283–92
   PubMed Web of Science ®Google Scholar
• Zhu L, Ge G, Liu Y, et al. (2012a). Characterization of UDP-glucuronosyltransferases involved in glucuronidation of diethylstilbestrol in human liver and intestine. Chem Res Toxicol 25:2663–9
   PubMed Web of Science ®Google Scholar
• Zhu L, Ge G, Liu Y, et al. (2012b). Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9. Xenobiotica 42:1001–8
   PubMed Web of Science ®Google Scholar
• Zhu L, Ge G, Zhang H, et al. (2012c). Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 40:529–38
   PubMed Web of Science ®Google Scholar